Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NBI-1065890 in Adult Participants With Tardive Dyskinesia
NCT07365462Phase 2Recruiting
- Sponsor
- Neurocrine Biosciences
- Start
- Feb 2026
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of NBI-1065890 in tardive dyskinesia (TD), sponsored by Neurocrine Biosciences. Started Feb 2026; status: recruiting.
02
Drugs
NBI-1065890
03
Conditions
tardive dyskinesia (TD)
Beyond the preview
Go deeper on NCT07365462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07365462.